Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Assets (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Non-Current Assets for 16 consecutive years, with $86.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 2.44% to $86.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $351.2 million through Dec 2025, down 11.49% year-over-year, with the annual reading at $86.9 million for FY2025, 2.44% down from the prior year.
  • Non-Current Assets for Q4 2025 was $86.9 million at Anika Therapeutics, down from $87.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $188.8 million in Q1 2021, with the low at $86.9 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $142.3 million, with a median of $174.0 million recorded in 2023.
  • The sharpest move saw Non-Current Assets increased 1.03% in 2023, then crashed 44.39% in 2024.
  • Over 5 years, Non-Current Assets stood at $179.0 million in 2021, then grew by 0.32% to $179.6 million in 2022, then crashed by 40.24% to $107.3 million in 2023, then dropped by 16.99% to $89.1 million in 2024, then fell by 2.44% to $86.9 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $86.9 million, $87.8 million, and $88.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.